Javier Munoz

ZUMA-12: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel as a First-Line Therapy in Patients With High-Risk Large B Cell Lymphoma

Purpose of the Study: Patients with large B cell lymphoma (LBCL) who have persistent disease assessed by dynamic positron emission tomography after rituximab-based induction therapy have ...

Jun Kawashima ;

Alex F. Herrera ;

Sven de Vos , MD, PhD;

Sattva S. Neelapu ;

Julio C. Chavez ;

Yi Lin ;

Javier Munoz ;

Lovely Goyal ;

Chaitra S. Ujjani ;

Peter Riedell ;

Olalekan O. Oluwole ;

Natasha Kekre ;

Kate Backhouse ;

Francesca Milletti ;

10/22/2019

Outcomes of Patients Aged 65 Years in ZUMA-1, a Pivotal Phase 1/2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Refractory Large B Cell Lymphoma

Purpose of the Study: Axicel is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved by the US Food and Drug Administration for the treatment of patients with r...

Sattva S. Neelapu ;

Javier Munoz ;

Olalekan O. Oluwole ;

Caron A. Jacobson ;

Abhinav Deol ;

David B. Miklos ;

Nancy L. Bartlett , MD;

Ira Braunschweig ;

Yizhou Jiang ;

Jenny J. Kim ;

Lianging Zheng ;

John M. Rossi ;